Mobio Interactive

Mobio Interactive operates at the intersection of digital health, software, therapeutics, and mental-health care. Its stated differentiation is the combination of remotely delivered psychotherapy with objective digital biomarkers intended to personalize care, including computer-vision and biosensing approaches that do not require a wearable. Its products span the AmDTx digital therapeutic platform, the Epígnosi mindful-eating program, and the TruSelf Dawn DTx brain-health challenge. The company is privately held, has a seed-stage funding profile, and has raised $4.4 million in total. More broadly, Mobio is addressing a market that includes digital mental-health services and therapeutics, where providers may differ in clinical validation, delivery model, and measurement methods.

Mobio Interactive’s development spans more than a decade, from its 2015 founding to a product portfolio that includes the AmDTx digital therapeutic platform and the Epígnosi program. Its financing history shows an early $550,000 pre-seed round in 2017, a $1.8 million seed round in 2020, a further seed round in 2022 with no disclosed amount, a $50,000 grant in 2023, and a $2 million seed round on April 14, 2025. In July 2026, the company partnered with the Ontario Brain Institute on a free five-day brain-health challenge using facial biometrics and personalized stress reports, extending its technology into a public-facing initiative. The company is listed in the 11–50 employee range. A separate growth signal describes work launched in Southwestern India in January 2025 alongside expansion of research pipelines and hospital partnerships, but does not quantify hiring, sites, or commercial results.